Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men | Zendy

Richard A. Anderson | Zendy; Jennifer Cormier | Zendy; Ruth ThieroffEkerdt | Zendy; Malcolm Boyce | Zendy; Frans van den Berg | Zendy; Daniel Grau | Zendy; David J. Turnquist | Zendy; Deya Corzo | Zendy; Philip B. Graham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men

Author(s) -

Richard A. Anderson,

Jennifer Cormier,

Ruth ThieroffEkerdt,

Malcolm Boyce,

Frans van den Berg,

Daniel Grau,

David J. Turnquist,

Deya Corzo,

Philip B. Graham

Publication year - 2020

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgaa657

Subject(s) - pharmacodynamics , medicine , endocrinology , placebo , pharmacokinetics , testosterone (patch) , cmax , antagonist , luteinizing hormone , pharmacology , receptor , hormone , alternative medicine , pathology

SJX-653 is a novel neurokinin 3 receptor (NK3R) antagonist. The NK3 pathway is a central regulator of gonadotropin releasing hormone (GnRH) secretion and has also been implicated in the generation of hot flashes. Therefore, decreases of luteinizing hormone (LH) and testosterone in men serve as sensitive pharmacodynamic (PD) markers of central NK3 antagonism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research